Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma
- R. Motzer, N. Tannir, +29 authors B. Escudier
- The New England journal of medicine
- 21 March 2018
Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate‐ and poor‐risk patients with previously untreated advanced renal‐cell carcinoma. Expand
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
The outcomes of a cohort of patients with cancer and COVID-19 are characterised and potential prognostic factors for mortality and severe illness are identified and race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality. Expand
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
The randomised phase 3 METEOR trial compared the efficacy and safety of cabozantinib versus the mTOR inhibitor everolimus in patients with advanced renal cell carcinoma who progressed after previous VEGFR tyrosine-kinase inhibitor treatment. Expand
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
- T. Choueiri, B. Escudier, +21 authors R. Motzer
- The New England journal of medicine
- 4 November 2015
Progression-free survival was longer with cabozantinib than with everolimus among patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy. Expand
Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
The hypothesis that patients with “anaplastic” prostate cancer are a recognizable subset characterized by a high response rate of short duration to platinum-containing chemotherapies, similar to SCPC is supported. Expand
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Results showed that nivolumab plus ipilimumab continued to be superior to sunitinib in terms of overall survival and characterisation of response, and safety after extended follow-up in intermediate-risk or poor-risk patients. Expand
VirusSeq: software to identify viruses and their integration sites using next-generation sequencing of human cancer tissue
- Yunxin Chen, Hui Yao, Erika J. Thompson, N. Tannir, J. Weinstein, X. Su
- Biology, Computer Science
- 15 January 2013
A new algorithmic method, VirusSeq, that accurately detects the known viruses and their integration sites in the human genome using next-generation sequencing data and can also perform this function using whole-genome sequencing data of human tissue. Expand
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.
This randomized phase 2 trial provides the first head-to-head comparison of everolimus and sunitinib in patients with metastatic non-clear cell renal cell carcinoma (non-ccRCC). Expand
Renal cell carcinoma: diagnosis, staging, and surveillance.
- C. Ng, C. Wood, P. Silverman, N. Tannir, P. Tamboli, C. Sandler
- AJR. American journal of roentgenology
- 1 October 2008
The incidence of renal cell carcinoma has been increasing and imaging plays a central role in its detection, staging, and treatment evaluation and follow-up. Expand
Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience
- O. Mamlouk, U. Selamet, +16 authors A. Abudayyeh
- Journal of Immunotherapy for Cancer
- 6 January 2019
Cases of biopsy proven acute tubulointerstitial nephritis and glomerulonephritis induced by immune checkpoint inhibitors are presented and it is demonstrated that ATIN is the most common pathological finding; however it can frequently co-occur with other glomerular pathologies, which may require immune suppressive therapy beyond corticosteroids. Expand